$35.98
00.00%
Last update: 9:29 AM
15 minutes delayed
Comments
Loading...
Biohaven
BHVNNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Biohaven (NYSE:BHVN) Stock, Analyst Ratings, Price Targets, Forecasts
Biohaven Ltd has a consensus price target of $91.44 based on the ratings of 17 analysts. The high is $170 issued by Goldman Sachs on October 6, 2021. The low is $24 issued by SVB Leerink on January 24, 2023. The 3 most-recent analyst ratings were released by RBC Capital, HC Wainwright & Co., and HC Wainwright & Co. on June 18, 2024, May 30, 2024, and May 13, 2024, respectively. With an average price target of $59 between RBC Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 63.98% upside for Biohaven Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
UBS
TD Cowen
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Biohaven
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/18/2024 | Buy Now | 63.98% | RBC Capital | Leonid Timashev | $59 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2024 | Buy Now | 63.98% | HC Wainwright & Co. | Douglas Tsao | $59 → $59 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 05/13/2024 | Buy Now | 63.98% | HC Wainwright & Co. | Douglas Tsao | $63 → $59 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 66.76% | UBS | Ashwani Verma | $59 → $60 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 04/09/2024 | Buy Now | 69.54% | RBC Capital | Leonid Timashev | → $61 | Reiterates | Outperform → Outperform | Get Alert |
| 03/04/2024 | Buy Now | 75.1% | HC Wainwright & Co. | Douglas Tsao | $50 → $63 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 69.54% | RBC Capital | Leonid Timashev | $62 → $61 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 52.86% | TD Cowen | Tyler Van Buren | $35 → $55 | Maintains | Outperform | Get Alert |
| 02/23/2024 | Buy Now | 55.64% | JP Morgan | Tessa Romero | $32 → $56 | Maintains | Overweight | Get Alert |
| 02/16/2024 | Buy Now | 72.32% | RBC Capital | Leonid Timashev | → $62 | Initiates | → Outperform | Get Alert |
| 02/06/2024 | Buy Now | 63.98% | UBS | Ashwani Verma | → $59 | Initiates | → Buy | Get Alert |
| 12/22/2023 | Buy Now | 38.97% | HC Wainwright & Co. | Douglas Tsao | → $50 | Initiates | → Buy | Get Alert |
| 12/08/2023 | Buy Now | 61.2% | Baird | Brian Skorney | → $58 | Initiates | → Outperform | Get Alert |
| 11/20/2023 | Buy Now | -11.06% | JP Morgan | Tessa Romero | $26 → $32 | Maintains | Overweight | Get Alert |
| 11/15/2023 | Buy Now | 0.06% | Piper Sandler | Christopher Raymond | $29 → $36 | Maintains | Overweight | Get Alert |
| 08/16/2023 | Buy Now | -33.3% | JP Morgan | Tessa Romero | $27 → $24 | Maintains | Overweight | Get Alert |
| 07/17/2023 | Buy Now | -13.84% | Cantor Fitzgerald | Charles Duncan | → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 06/06/2023 | Buy Now | -22.18% | BTIG | Thomas Shrader | → $24 | Reiterates | → Buy | Get Alert |
| 04/04/2023 | Buy Now | -13.84% | Cantor Fitzgerald | Charles Duncan | $27 → $31 | Maintains | Overweight | Get Alert |
| 01/24/2023 | Buy Now | -33.3% | SVB Leerink | Marc Goodman | → $24 | Initiates | → Outperform | Get Alert |
| 01/04/2023 | Buy Now | -36.08% | JP Morgan | Tessa Romero | → $23 | Initiates | → Overweight | Get Alert |
| 12/02/2022 | Buy Now | -33.3% | BTIG | Thomas Shrader | → $24 | Initiates | → Buy | Get Alert |
| 10/26/2022 | Buy Now | -41.63% | Piper Sandler | Christopher Raymond | $23 → $21 | Maintains | Overweight | Get Alert |
| 10/12/2022 | Buy Now | -36.08% | Piper Sandler | Christopher Raymond | → $23 | Initiates | → Overweight | Get Alert |
| 08/19/2022 | Buy Now | — | Piper Sandler | Christopher Raymond | — | Downgrade | Overweight → Neutral | Get Alert |
| 08/08/2022 | Buy Now | 312.73% | Wedbush | Laura Chico | → $148.5 | Downgrade | Outperform → Neutral | Get Alert |
| 05/11/2022 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao | — | Downgrade | Buy → Neutral | Get Alert |
| 05/11/2022 | Buy Now | 312.73% | Morgan Stanley | Jeffrey Hung | $146 → $148.5 | Maintains | Equal-Weight | Get Alert |
| 05/11/2022 | Buy Now | — | SVB Leerink | Marc Goodman | — | Downgrade | Outperform → Market Perform | Get Alert |
| 04/06/2022 | Buy Now | 305.78% | Morgan Stanley | Jeffrey Hung | $148 → $146 | Maintains | Equal-Weight | Get Alert |
| 03/03/2022 | Buy Now | 328.02% | Mizuho | Vamil Divan | $144 → $154 | Maintains | Buy | Get Alert |
| 01/07/2022 | Buy Now | 311.34% | Morgan Stanley | Matthew Harrison | $145 → $148 | Maintains | Equal-Weight | Get Alert |
| 11/18/2021 | Buy Now | 300.22% | Mizuho | Vamil Divan | — | Maintains | Buy | Get Alert |
| 11/10/2021 | Buy Now | 275.21% | Mizuho | Vamil Divan | — | Maintains | Buy | Get Alert |
| 10/19/2021 | Buy Now | 303% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 10/06/2021 | Buy Now | 372.48% | Goldman Sachs | Paul Choi | — | Maintains | Buy | Get Alert |
| 10/06/2021 | Buy Now | 344.69% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 10/05/2021 | Buy Now | 333.57% | Piper Sandler | Christopher Raymond | — | Maintains | Overweight | Get Alert |
| 09/13/2021 | Buy Now | 358.59% | Cantor Fitzgerald | Charles Duncan | — | Maintains | Overweight | Get Alert |
| 08/10/2021 | Buy Now | 202.95% | UBS | Esther Rajavelu | — | Downgrade | Buy → Neutral | Get Alert |
| 08/03/2021 | Buy Now | 316.9% | Canaccord Genuity | Sumant Kulkarni | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Biohaven (BHVN) stock?
The latest price target for Biohaven (NYSE:BHVN) was reported by RBC Capital on June 18, 2024. The analyst firm set a price target for $59.00 expecting BHVN to rise to within 12 months (a possible 63.98% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Biohaven (BHVN)?
The latest analyst rating for Biohaven (NYSE:BHVN) was provided by RBC Capital, and Biohaven reiterated their outperform rating.
When was the last upgrade for Biohaven (BHVN)?
There is no last upgrade for Biohaven
When was the last downgrade for Biohaven (BHVN)?
The last downgrade for Biohaven Ltd happened on August 19, 2022 when Piper Sandler changed their price target from N/A to N/A for Biohaven Ltd.
When is the next analyst rating going to be posted or updated for Biohaven (BHVN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biohaven, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biohaven was filed on June 18, 2024 so you should expect the next rating to be made available sometime around June 18, 2025.
Is the Analyst Rating Biohaven (BHVN) correct?
While ratings are subjective and will change, the latest Biohaven (BHVN) rating was a reiterated with a price target of $59.00 to $59.00. The current price Biohaven (BHVN) is trading at is $35.98, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.